Atrial fibrillation and obstructive sleep apnea in African populations: uncovering a neglected association

Jean Jacques Noubiap

**Corresponding author:** Jean Jacques Noubiap, Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia. noubiapjj@yahoo.fr

Received: 22 Mar 2021 - Accepted: 02 May 2021 - Published: 20 May 2021

Keywords: Atrial fibrillation, obstructive sleep apnea, Africa

**Copyright:** Jean Jacques Noubiap et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Cite this article:** Jean Jacques Noubiap et al. Atrial fibrillation and obstructive sleep apnea in African populations: uncovering a neglected association. Pan African Medical Journal. 2021;39(55). 10.11604/pamj.2021.39.55.29000

Available online at: https://www.panafrican-med-journal.com/content/article/39/55/full

Atrial fibrillation and obstructive sleep apnea in African populations: uncovering a neglected association

Jean Jacques Noubiap

1Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia

**Abstract**

Atrial fibrillation (AF), the most common sustained arrhythmia, is one of the risk factors with the largest relative increase in attributed cardiovascular mortality in Africa. There are important knowledge gaps in the epidemiology of AF in Africa, along with inadequate service
provision for cardiac arrhythmias including AF. This paper comments on the available data on the prevalence and correlates of obstructive sleep apnea (OSA) in patients with AF in Africa. Two studies from Tunisia revealed a high prevalence of OSA based on polysomnography (77% and 90%) among patients with AF. Patients with OSA were more likely to report snoring, were older and had longer AF duration compared to those without OSA. The implications of these findings are discussed. Furthermore, key points on the mechanisms underlying the association between AF and OSA, the impact of OSA on AF-related outcomes and the screening and management of OSA in patients with AF are highlighted.

Commentary

Atrial fibrillation (AF), the most common sustained arrhythmia, is a growing global epidemic. There were 37.6 million individuals who were affected (0.51% of global population) in 2017, including 3.046 million new cases [1]. This represents a 33% increase in the prevalence of AF during the last two decades [1]. Atrial fibrillation is associated with substantial morbidity and mortality. Individuals with AF have a five-fold increased risk of stroke, three-fold increased risk of heart failure and almost two-fold increased risk of overall mortality [2,3]. It is estimated that 0.287 million deaths and 5976 million disability-adjusted life years were attributable to AF in 2017 [1]. Although the very few population-based studies conducted in Africa have suggested a low prevalence of AF in the general population [4], according to some projections there will be more people with AF in Africa than in either China, the United States, or India by 2050 [5]. Atrial fibrillation is one of the risk factors with the largest relative increase in attributed cardiovascular mortality in Africa [6]. Moreover, the economic cost of AF is likely to be substantial in African countries [7]. Several studies along with the recent report of the Pan African Society of Cardiology (PASCAR) on cardiac arrhythmia services in Africa (2011-2018) have shown that the management of AF in Africa is challenging, due to limited infrastructural, financial and human resources [4,7]. The important knowledge gaps in the epidemiology of AF on the continent also contributes to inadequate service provision.

Obstructive sleep apnea (OSA) is increasingly recognized as a major problem in patients with AF [8]. We performed a systematic search of PubMed and African Journals Online to identify studies on the prevalence and correlates of OSA in patients with non-valvular AF in Africa. Two studies were identified, both from Tunisia [9,10]. In the most recent one, Manel Ben Halima and colleagues included 100 patients with non-valvular AF, with a mean age of 66.4 years, 45% male (Table 1) [9]. According to the Berlin questionnaire, 64% of patients had a high probability of OSA (score ≥ 2). Based on polysomnography, 90% of patients had OSA (Apnea Hypopnea Index (AHI) ≥ 5 episodes/hour), including 32% with mild (AHI 5-14), 27% with moderate (AHI 15-29), and 31% with severe OSA (AHI ≥30). Factors independently associated with a diagnosis of OSA included age > 61 years (adjusted odds ratio [aOR] 12.8, 95% confidence interval [CI]: 1.30-127.74; p = 0.029), AF duration > 2 years (aOR 6.4, 95% CI: 1.05-39.87; p = 0.044) and snoring (aOR 18.9, 95% CI: 1.62-221.13, p = 0.019) [9]. In the other study, Afef Ben Halima and colleagues reported on a group of 73 patients with AF and hypertension, with a mean age of 66.6 years and 21.9% of males [10]. The Berlin questionnaire identified 84% of patients with a high probability of OSA, whereas 77% (n = 56) of patients had a confirmed diagnosis of OSA (AHI ≥5) with polysomnography, including 18% with mild (AHI 5-14), 15% with moderate (AHI 15-29), and 44% with severe OSA (AHI ≥30) (Figure 1).

Despite the small sample sizes and a selection bias towards patients with poor cardiometabolic profile that both limit the generalizability of their findings, the main strength of these studies is the use of polysomnography, the reference standard for the diagnosis and severity assessment of OSA. The frequency of OSA in these two studies from Tunisia is higher than rates between 21% and 74% reported
by previous studies in various settings [8]. The wide variance in prevalence rates across studies is mainly due to differences in sensitivity of sleep-study recording techniques and scoring criteria, as well as in the risk profile of study populations. For instance, the cutoff AHI score used for the diagnosis of OSA in various studies ranges between 5 and 15 episodes per hour [8]. Moreover, whereas some studies investigating the prevalence of OSA included patients with AF and various risk profiles, others focused on patients undergoing AF ablation, with mostly longstanding AF resistant to pharmacotherapy and therefore, who are more likely to have OSA [8].

Atrial fibrillation and OSA frequently co-exist due to shared risk factors including obesity, hypertension, and diabetes that are increasingly prevalent in the general population [8,11]. Obstructive sleep apnea is also an important risk factor for the occurrence and progression of AF [8,11,12]. First, acute apnea is associated with an increase in atrial arrhythmogenesis through several mechanisms. Negative intrathoracic pressure swings during obstructed inspiration and causes acute atrial dilation that shortens atrial refractoriness, slows conduction, and increases the occurrence of intermittent conduction delay [8]. Furthermore, the sympathovagal activation caused by obstructed breathing efforts induces acute electrophysiological arrhythmogenic changes that could trigger AF in a vulnerable substrate [8]. Second, in the long-term, OSA is associated with marked atrial structural and electrical changes. Intermittent episodes of deoxygenation and reoxygenation lead to oxidative stress that, along with chronic neurohormonal activation contribute to atrial fibrosis [8]. Repetitive mechanical atrial stretch from recurrent obstructive respiratory episodes also causes myocardial injury and remodeling, as well as regional conduction slowing and reentry [8]. All these OSA-induced changes are exacerbated by concomitant conditions such as obesity, hypertension and diabetes, and ultimately constitute a complex and dynamic arrhythmogenic substrate for AF [8].

The presence and severity of OSA have a substantial impact on AF outcomes. Although the evidence is limited, OSA has been reported as an independent predictor of stroke in patients with AF [13]. Obstructive sleep apnea significantly reduces the effectiveness of rhythm control strategies including antiarrhythmic drug therapy and catheter-based pulmonary vein isolation [14-16]. Additionally, several non-randomized observational studies and meta-analyses showed that treatment of OSA by continuous positive airway pressure (CPAP) may improve success rates after catheter ablation in patients with AF [14,17]. As a result, the 2020 European Society of Cardiology (ESC) guidelines for the diagnosis and management of AF indicate that: 1) opportunistic screening for AF should be considered in patients with OSA (class IIa, level C) and; 2) optimal management of OSA may be considered, to reduce AF incidence, AF progression, AF recurrences, and symptoms (class IIb, level C) [18]. In terms of screening for OSA in patients with AF, whereas the 2016 ESC guidelines acknowledge that the interrogation for clinical signs of OSA should be considered in all AF patients (class IIa, level C) [19], the 2020 ESC guidelines acknowledge that it remains unclear how and when to test for OSA and implement OSA management in the standard work-up of patients with AF [18].

In the light of this body of knowledge on the association between OSA and AF, and the current related recommendations from international professional societies [18,19], the findings of the studies by Afef Ben Halima and Manel Ben Halima and their colleagues have few implications [9,10]. Considering its potentially high prevalence and its adverse effects, OSA should receive enough attention from physicians managing patients with AF in African settings. There is no specific data on the availability and affordability of polysomnography and CPAP in various African health facilities. Manel Ben Halima et al. acknowledged a limited accessibility to polysomnography in their context [9]. The situation is probably similar or even worse in the vast majority of health facilities across the continent.
which are very resource-constrained. Considering the low affordability and availability of basic medications for cardiovascular disease in Africa [20,21], a more expensive therapy like CPAP would probably not be accessible to a large proportion of patients who need it. In this context, lifestyle interventions for the prevention and control of OSA are of utmost importance.

Indeed, the role of risk factor control targeting hypertension, diabetes, obesity, dyslipidemia, OSA, physical inactivity and alcohol consumption is now recognized as a major component in the management of patients with AF [18]. Patients with AF and OSA should be screened for exacerbating factors such as obesity and alcohol consumption. Alcohol consumption prior to bedtime has been associated with more frequent and longer episodes of hypopnea and apnea in people who snore or have OSA [22]. Furthermore, obesity is strongly associated with OSA and, in more extreme cases, obesity hypoventilation syndrome [11]. There are compelling evidence showing that significant and sustained weight loss, if achieved, is likely to be a useful therapeutic option in the management of OSA [23]. Thus, weight reduction and alcohol cessation should be strongly encouraged in patients with AF and OSA. In a context of limited availability of polysomnography, questionnaires such as the Epworth Sleepiness Scale or the Berlin questionnaire remain very useful in identifying patients with a high probability of OSA and who should consider costless lifestyle interventions. Nevertheless, CPAP should not be overlooked and should be offered whenever indicated and available, especially in patients with severe OSA. Such contextualized approaches might contribute in reducing the adverse effects of OSA in patients with AF in resource-limited settings in Africa.

Disclosures: Dr Noubiap is supported by a Postgraduate Scholarship from the University of Adelaide.

Competing interests

The author declares no competing interest.

Authors' contributions

The author has read and agreed to the final manuscript.

Table and figure

Table 1: characteristics of studies on obstructive sleep apnea in patients with atrial fibrillation in Africa

Figure 1: proportion of patients with obstructive sleep apnea; OSA: obstructive sleep apnea; overall OSA: Apnea-Hypopnea Index (AHI, in episodes per hour) ≥ 5; mild OSA: 5-14; moderate OSA: AHI 15-29; Severe OSA: AHI ≥ 30

References

1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2): 217-221. PubMed| Google Scholar
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23): 2920-5. PubMed| Google Scholar
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8): 983-8. PubMed| Google Scholar
4. Noubiap JJ, Nyaga UF. A review of the epidemiology of atrial fibrillation in sub-Saharan Africa. J Cardiovasc Electrophysiol. 2019;30(12): 3006-3016. PubMed| Google Scholar
5. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11): 639-54. PubMed| Google Scholar
6. Moran A, Forouzanfar M, Sampson U, Chugh S, Feigin V, Mensah G. The epidemiology of cardiovascular diseases in sub-Saharan Africa: the global burden of diseases, injuries and risk factors 2010 study. Prog Cardiovasc Dis. 2013;56(3): 234-9. PubMed | Google Scholar

7. Bonny A, Ngantcha M, Scholtz W, Chin A, Nel G, Anzouan-Kacou JB et al. Cardiac Arrhythmias in Africa: epidemiology, management challenges and perspectives. J Am Coll Cardiol. 2019;73(1): 100-109. PubMed | Google Scholar

8. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018;3(6): 532-540. PubMed | Google Scholar

9. Ben Halima M, Sammoud K, Ben Amar J, Boudiche S, Rekik B, Mghaieth F et al. Prevalence and predictors of sleep apnea in atrial fibrillation patients. Tunis Med. 2020;98(12): 1031-1038. PubMed | Google Scholar

10. Ben Halima A, Aouadi S, Beijjar D, Laroussi L, Boukhris M, Gharbi L et al. Hypertension and atrial fibrillation: what is the prevalence of obstructive sleep apnea syndrome. Tunis Med. 2018;96(3): 187-192. PubMed | Google Scholar

11. Gami AS, Hodge DO, Hedges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5): 565-71. PubMed | Google Scholar

12. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4): 364-7. PubMed | Google Scholar

13. Yaranov DM, Smyrlis A, Usatii N, Butler A, Pettrini JR, Mendez J et al. Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. Am J Cardiol. 2015;115(4): 461-5. PubMed | Google Scholar

14. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2(6): e000421. PubMed | Google Scholar

15. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108(1): 47-51. PubMed | Google Scholar

16. Monahan K, Brewster J, Wang L, Parvez B, Goyal S, Roden DM et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110(3): 369-72. PubMed | Google Scholar

17. Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC Clin Electrophysiol. 2015;1(1-2): 41-51. PubMed | Google Scholar

18. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5): 373-498. PubMed | Google Scholar

19. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11): 1609-1678. PubMed | Google Scholar

20. Jingi AM, Noubiap JJ, Ewane Onana A, Nansseu JR, Wang B, Kingue S et al. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon. PLoS One. 2014;9(11): e111812. PubMed | Google Scholar
21. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc. 2020;9(9): e015302. PubMed | Google Scholar

22. Scanlan MF, Roebuck T, Little PJ, Redman JR, Naughton MT. Effect of moderate alcohol upon obstructive sleep apnoea. Eur Respir J. 2000;16(5): 909-13. PubMed | Google Scholar

23. Cowan DC, Livingston E. Obstructive sleep apnoea syndrome and weight loss: review. Sleep Disord. 2012;2012: 163296. PubMed | Google Scholar

Table 1: characteristics of studies on obstructive sleep apnea in patients with atrial fibrillation in Africa

| Characteristics                  | Afef Ben Halima, 2018 | Manel Ben Halima, 2020 |
|----------------------------------|-----------------------|------------------------|
|                                  | Total sample (n = 73) | Patients with OSA (n = 56) | Patients without OSA (n = 17) | P value | Total sample (n = 100) | Patients with OSA (n = 90) | Patients without OSA (n = 10) | P value |
| Demographics                     |                       |                        |                            |         |                       |                        |                                |         |
| Age (years)                      | 66.6 (10.7)           | 66.7 (10.9)            | 65.9 (10.2)                | 0.70    | 66.4 (9.7)            | 67.6 (8.6)            | 56.1 (13.0)                | 0.01    |
| Males                            | 21.9%                 | 26.8%                  | 5.9%                       | 0.06    | 45%                   | 45%                   | 40%                        | 0.70    |
| Anthropometry                    |                       |                        |                            |         |                       |                        |                                |         |
| BMI (kg/m2)                      | 34.6 (6.5)            | 35 (6.8)               | 33.4 (5.0)                 | 0.30    | 28.5 (4.8)            | 28.6 (4.9)            | 27.7 (3.9)                 | 0.58    |
| Neck circumference (cm)          | 38.8 (4.0)            | NR                     | NR                         | 0.10    | 38.8 (4.9)            | 38.4 (4.8)            | 0.62                        |         |
| Risk factors                     |                       |                        |                            |         |                       |                        |                                |         |
| Hypertension                     | 100%                  | 100%                   | 100%                       | 1.00    | 72%                   | 73.3%                  | 60%                        | 0.37    |
| Diabetes                         | 26%                   | 29%                    | 18%                        | 0.30    | 31%                   | 28.8%                  | 50%                        | 0.17    |
| Dyslipidemia                     | 26%                   | 26%                    | 29%                        | 0.70    | 45%                   | 45.5%                  | 40%                        | 0.70    |
| Tobacco smoking                  | 19.2%                 | 23%                    | 6%                         | 0.10    | 25%                   | 26.6%                  | 10%                        | 0.47    |
| AF characteristics               |                       |                        |                            |         |                       |                        |                                |         |
| AF duration (years)              | 4.5 (5.6)             | 4.7 (5.7)              | 4.1 (5.6)                  | 0.50    | 4.4                   | 4.4                    | 4.1                        | 0.02    |
| Chronic AF                       | NR                    | NR                     | NR                         | 76%     | 77.8%                 | 60%                    | 0.21                       |         |
| Asymptomatic AF (EHRA I)         | NR                    | NR                     | NR                         | 18%     | 15.6%                 | 40%                    | 0.06                       |         |
| Symptoms                         |                       |                        |                            |         |                       |                        |                                |         |
| Snoring                          | NR                    | NR                     | NR                         | 87%     | 90%                   | 60%                    | 0.02                       |         |
| Sleep disorders                  | NR                    | NR                     | NR                         | 60%     | 62.2%                 | 40%                    | 0.17                       |         |
| Nocturia                         | NR                    | NR                     | NR                         | 56%     | 55.5%                 | 60%                    | 0.78                       |         |
| Daytime sleepiness               | 67.1%                 | 68%                    | 65%                        | 0.90    | 80%                   | 81%                    | 70%                        | 0.40    |
| Epworth score                    | NR                    | 7 (6)                  | 5.4 (4.6)                  | 0.30    | 10.3 (4.1)            | 10.5 (4.1)            | 9 (4.5)                    | 0.20    |
| Memory impairment                | NR                    | NR                     | NR                         | 73%     | 74.4%                 | 60%                    | 0.33                       |         |
| Morning fatigue                  | NR                    | NR                     | NR                         | 66%     | 66.6%                 | 60%                    | 0.67                       |         |
| Cognitive impairment             | 16.4%                 | 21%                    | 0%                         | 0.03    | 41%                   | 42.2%                  | 30%                        | 0.45    |

AF: atrial fibrillation; BMI: body mass index; EHRA: European Heart Rhythm Association; OSA: obstructive sleep apnea; NR: not reported

Jean Jacques Noubiap et al. PAMJ - 39(55). 20 May 2021. - Page numbers not for citation purposes.
Figure 1: proportion of patients with obstructive sleep apnea; OSA: obstructive sleep apnea; overall OSA: Apnea-Hypopnea Index (AHI, in episodes per hour) ≥ 5; mild OSA: 5-14; moderate OSA: AHI 15-29; Severe OSA: AHI ≥ 30